Mesothelioma durvalumab clinical trials are testing the safety and effectiveness of this immunotherapy drug for pleural mesothelioma patients. This is also a targeted therapy that may only work for cancers that express a specific protein. The FDA has approved durvalumab to treat bladder cancer and non-small cell lung cancer. What Is Durvalumab? Durvalumab is made
Opdivo (nivolumab) and Yervoy (ipilimumab) are immunotherapy drugs approved to treat pleural mesothelioma. The National Comprehensive Cancer Network (NCCN) recommends that physicians use a combination of both agents for treating mesothelioma that has progressed through an initial first-line treatment. What Is Nivolumab and Ipilimumab Combination Mesothelioma Treatment? In 2020, the U.S. Food and Drug Administration
VISTA protein clinical trials recently tested a drug known as CA-170 for its potential effectiveness as a type of cancer therapy. CA-170 is an immunotherapy drug that prevents the deactivation of immune system T-cells by cancer cells. The trials, which included mesothelioma patients, recently concluded. What Is VISTA? Immune Checkpoint Proteins and Inhibitors VISTA (V-domain
Mesothelioma is an equal opportunity disease. It impacts everybody who has been exposed to asbestos, regardless of age, gender, or other demographic information. However, not everybody is equally at risk for exposure to asbestos. It has long been known that there are certain occupations that historically had a higher degree of exposure to the carcinogenic
Once a victim of asbestos exposure is diagnosed with mesothelioma, they have numerous decisions to make, and one of the most important for their family is whether or not to pursue legal action against the company that exposed them to the carcinogenic material. Filing a mesothelioma lawsuit can lead to significant compensation that both pays
Biotech company Curis, Inc., a leader in innovative cancer treatments, has announced that as part of a Phase I clinical trial of their new drug CA-170, they’ve enrolled and dosed their first mesothelioma patient. The oral medication targets cancer cells that express high levels of VISTA, a protein understood to help cancer cells resist treatment.
Mesothelioma, a rare and aggressive cancer caused by asbestos exposure, is usually a terminal diagnosis. Knowing how to survive mesothelioma means using best practices to extend life as much as possible: getting an early diagnosis and undergoing aggressive treatments. Not everyone will survive mesothelioma, but victims of asbestos exposure can find hope and inspiration in
One of the most valuable things in a mesothelioma patient’s life is time. Time to spend with family. Time to address their legacy. Time to do the things that they have long dreamed of doing. In the face of a terminal diagnosis, most find themselves frustrated by how much time they spend in the hospital
Mesothelioma patients who opt to seek alternative therapies for the treatment of their condition may end up losing their battle against the fatal disease even faster than they would have had they limited their treatment to the use of traditional therapies. According to a study published in the journal JAMA Oncology, the fault lies less with
Mesothelioma rates in Vietnam veterans are high because of decades of asbestos use by the U.S. military. Veterans exposed to asbestos during service, who later become ill, may file for VA benefits like disability compensation and health care. How Did the Military Use Asbestos? The heaviest use of asbestos by the U.S. military was between